National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic Evaluation of Natalizumab (Tysabri®) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
January 2007 April 2007 Reimbursement recommended.

Natalizumab could be considered borderline cost effective in the Irish healthcare setting. In view of the uncertainty surrounding some of the ICERs a follow up review is advised. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.

Natalizumab (Tysabri®) summary